Roche Holding AG (RHHBY)
31.92
+0.61
(+1.95%)
USD |
OTCM |
Mar 28, 16:00
Roche Enterprise Value: 230.55B for March 28, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
March 28, 2024 | 230.55B |
March 27, 2024 | 226.66B |
March 26, 2024 | 226.66B |
March 25, 2024 | 226.53B |
March 22, 2024 | 226.72B |
March 21, 2024 | 226.72B |
March 20, 2024 | 235.01B |
March 19, 2024 | 231.82B |
March 18, 2024 | 232.20B |
March 15, 2024 | 235.14B |
March 14, 2024 | 236.73B |
March 13, 2024 | 245.22B |
March 12, 2024 | 251.15B |
March 11, 2024 | 247.70B |
March 08, 2024 | 243.17B |
March 07, 2024 | 242.35B |
March 06, 2024 | 240.43B |
March 05, 2024 | 238.39B |
March 04, 2024 | 236.67B |
March 01, 2024 | 237.94B |
February 29, 2024 | 235.71B |
February 28, 2024 | 236.99B |
February 27, 2024 | 237.63B |
February 26, 2024 | 234.37B |
February 23, 2024 | 237.18B |
Date | Value |
---|---|
February 22, 2024 | 234.18B |
February 21, 2024 | 236.86B |
February 20, 2024 | 235.78B |
February 16, 2024 | 232.84B |
February 15, 2024 | 231.69B |
February 14, 2024 | 231.18B |
February 13, 2024 | 231.89B |
February 12, 2024 | 234.88B |
February 09, 2024 | 233.03B |
February 08, 2024 | 231.69B |
February 07, 2024 | 234.56B |
February 06, 2024 | 239.16B |
February 05, 2024 | 238.45B |
February 02, 2024 | 243.49B |
February 01, 2024 | 245.85B |
January 31, 2024 | 251.08B |
January 30, 2024 | 255.80B |
January 29, 2024 | 255.42B |
January 26, 2024 | 254.27B |
January 25, 2024 | 249.30B |
January 24, 2024 | 251.98B |
January 23, 2024 | 250.83B |
January 22, 2024 | 253.57B |
January 19, 2024 | 252.36B |
January 18, 2024 | 252.93B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
226.53B
Minimum
Mar 25 2024
368.95B
Maximum
Dec 28 2021
287.82B
Average
287.57B
Median
Oct 29 2020
Enterprise Value Benchmarks
Novartis AG | 208.36B |
Pfizer Inc | 215.13B |
Gilead Sciences Inc | 108.88B |
Eli Lilly and Co | 762.05B |
CRISPR Therapeutics AG | 3.778B |
Enterprise Value Related Metrics
Earnings Yield | 6.27% |
Operating Earnings Yield | 8.39% |
Normalized Earnings Yield | 6.342 |